Plum to Lead HTGF: New Managing Director Announced
Portolio - People | Dec 09, 2024 | High-Tech Gruenderfonds Manage
Dr. Achim Plum is set to join High-Tech Gründerfonds (HTGF) as Managing Director starting January 1, 2025, succeeding Guido Schlitzer. This strategic appointment emphasizes HTGF's focus on enhancing its life science segment, a move supported by Dr. Plum's extensive 20-year experience in the industry. HTGF, known for its successful exits and financing rounds, including the acquisition of Cardior Pharmaceuticals by Novo Nordisk, aims to leverage Dr. Plum’s expertise in diagnostics, precision medicine, and medical technology. With HTGF managing over €2 billion across various sectors, Dr. Plum is poised to bolster its portfolio, aligning with HTGF's tripartite investment strategy in industrial tech, life sciences, and digital tech. As a seed-stage investor, HTGF continues to solidify its reputation in the start-up ecosystem with support from notable stakeholders including the German Federal Ministry for Economic Affairs and Climate Action.
Sectors
- Venture Capital
- Life Sciences
Geography
- Germany – HTGF is based in Germany and plays a significant role in the German start-up and venture capital ecosystem.
Industry
- Venture Capital – HTGF is an early-stage investor with a focus on venture capital, financing start-ups across various technology sectors.
- Life Sciences – The appointment of Dr. Plum aims to strengthen HTGF's investment focus on life sciences, reflecting its growing importance within their portfolio.
Financials
- 1.025 billion – Acquisition value of Cardior Pharmaceuticals by Novo Nordisk.
- 63 million – Follow-on financing round completed by HTGF portfolio company SciRhom.
- 128 million – Follow-on financing round completed by HTGF portfolio company Tubulis.
- Over 2 billion euros – The amount managed by HTGF across its funds.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| Dr. Achim Plum | Incoming Managing Director | Person | Dr. Plum is appointed as HTGF's Managing Director, bringing significant experience in life sciences. |
| Guido Schlitzer | Outgoing Managing Director | Person | Prior Managing Director of HTGF, set to leave by December 31, 2024. |
| Romy Schnelle | Managing Director | Person | Part of the HTGF management team. |
| Dr. Alex von Frankenberg | Managing Director | Person | Part of the HTGF management team. |
| High-Tech Gründerfonds (HTGF) | Venture Capital Firm | Company | A leading early-stage investor in Germany managing over €2 billion in various high-tech sectors. |
| Novo Nordisk | Acquirer | Company | Global healthcare company that acquired HTGF's portfolio company, Cardior Pharmaceuticals. |
| Cardior Pharmaceuticals | Portfolio Company | Company | HTGF portfolio company recently acquired by Novo Nordisk for up to €1.025 billion. |
| Dr. Matthias Koehler | Chairman of Investor Advisory Board | Person | He oversees the HTGF Investor Advisory Board. |